| Dirk John Scholten, MD | |
|
412 Jefferson St, Pella, IA 50219-1257 | |
| (641) 628-9599 | |
| (641) 621-1493 |
| Full Name | Dirk John Scholten |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 412 Jefferson St, Pella, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164505376 | NPI | - | NPPES |
| 0239939 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 23432 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dirk John Scholten, MD 412 Jefferson St, Pella, IA 50219-1257 Ph: (641) 628-9599 | Dirk John Scholten, MD 412 Jefferson St, Pella, IA 50219-1257 Ph: (641) 628-9599 |
News Archive
Some of the greatest wonders of the 21st century will probably occur on a small scale – in fact a tiny scale – smaller than a human blood cell, right down there at the level of atoms and molecules.
Can the song of a small bird provide valuable insights into human stuttering and speech-related disorders and conditions, including autism and stroke? New research by UCLA life scientists and colleagues provides reason for optimism.
Urban children with persistent asthma living in homes with smokers are 10 times less likely to be protected by a smoking ban in the home and car than asthmatic children living with no smokers, according to a new study by researchers at the University of Rochester Medical Center.
Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announce today that they have initiated the first-in-human clinical study of OBT357 (MEN1112), a novel enhanced antibody for the treatment of acute myeloid leukemia (AML).
Ajinomoto AminoScience LLC (AAS) today announced that it has confirmed GRAS (Generally Recognized As Safe) status of its AjiGRAS-Leucine, meeting the safety standards demanded by the US Food and Drug Administration (FDA). As the only formulation of Leucine currently with FDA acknowledged GRAS status, Ajinomoto's AjiGRAS-Leucine is the first amino acid to be allowed as an ingredient for use in conventional foods like non-milk and milk based meal replacements, sports and isotonic beverages, vitamin enhanced waters, and meal replacement bars, at levels of 0.5 to 3 grams per serving.
› Verified 9 days ago
Dr. Michael Gary Walsh, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 710 W 1st St, Pella, IA 50219 Phone: 641-629-9222 |